Tenaya Shares Rise on Positive Data From ARVC Study

Dow Jones05-15

By Nicholas G. Miller

Tenaya Therapeutics shares rose after the company reported positive interim data from a trial of its gene therapy to treat arrhythmogenic right ventricular cardiomyopathy.

The stock rose 4.8% to 98 cents in premarket trading. It has more than doubled over the past 12 months.

The biotechnology company said the Phase 1b/2 trial demonstrated consistent and deep reductions in premature ventricular contractions.

Tenaya's chief medical officer, Whit Tingley, said the trial has shown consistent improvements in ventricular electrical stability, which is predicted to "decrease the risk for more serious, life-threatening arrhythmias."

The therapy was also well-tolerated at both dose levels in the study, the company said

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

May 15, 2026 07:14 ET (11:14 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635862200?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 19:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635862200","market":"hk","top_or_hot":-1,"title":"Tenaya Shares Rise on Positive Data From ARVC Study","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Tenaya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares rose after the company reported positive interim data from a trial of its gene therapy to treat arrhythmogenic right ventricular cardiomyopathy. \n</p>\n<p>\n  The stock rose 4.8% to 98 cents in premarket trading. It has more than doubled over the past 12 months. \n</p>\n<p>\n  The biotechnology company said the Phase 1b/2 trial demonstrated consistent and deep reductions in premature ventricular contractions. \n</p>\n<p>\n  Tenaya's chief medical officer, Whit Tingley, said the trial has shown consistent improvements in ventricular electrical stability, which is predicted to \"decrease the risk for more serious, life-threatening arrhythmias.\" \n</p>\n<p>\n  The therapy was also well-tolerated at both dose levels in the study, the company said \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 15, 2026 07:14 ET (11:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tenaya Shares Rise on Positive Data From ARVC Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenaya Shares Rise on Positive Data From ARVC Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-15 19:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Tenaya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares rose after the company reported positive interim data from a trial of its gene therapy to treat arrhythmogenic right ventricular cardiomyopathy. \n</p>\n<p>\n  The stock rose 4.8% to 98 cents in premarket trading. It has more than doubled over the past 12 months. \n</p>\n<p>\n  The biotechnology company said the Phase 1b/2 trial demonstrated consistent and deep reductions in premature ventricular contractions. \n</p>\n<p>\n  Tenaya's chief medical officer, Whit Tingley, said the trial has shown consistent improvements in ventricular electrical stability, which is predicted to \"decrease the risk for more serious, life-threatening arrhythmias.\" \n</p>\n<p>\n  The therapy was also well-tolerated at both dose levels in the study, the company said \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 15, 2026 07:14 ET (11:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNYA","symbol_name":"Tenaya Therapeutics Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2635862200","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635862200","pubTimestamp":1778843640,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Tenaya Therapeutics shares rose after the company reported positive interim data from a trial of its gene therapy to treat arrhythmogenic right ventricular cardiomyopathy.The stock rose 4.8% to 98 cents in premarket trading. It has more than doubled over the past 12 months.The biotechnology company said the Phase 1b/2 trial demonstrated consistent and deep reductions in premature ventricular contractions.Tenaya's chief medical officer, Whit Tingley, said the trial has shown consistent improvements in ventricular electrical stability, which is predicted to \"decrease the risk for more serious, life-threatening arrhythmias.\". The therapy was also well-tolerated at both dose levels in the study, the company said","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNYA":"Tenaya Therapeutics Inc","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"ARVC研究的积极数据使Tenaya股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNYA":0.9},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Tenaya Therapeutics shares rose after the company reported positive interim data from a trial of its gene therapy to treat arrhythmogenic right ventricular cardiomyopathy. \n\n\n  The stock rose 4.8% to 98 cents in premarket trading. It has more than doubled over the past 12 months. \n\n\n  The biotechnology company said the Phase 1b/2 trial demonstrated consistent and deep reductions in premature ventricular contractions. \n\n\n  Tenaya's chief medical officer, Whit Tingley, said the trial has shown consistent improvements in ventricular electrical stability, which is predicted to \"decrease the risk for more serious, life-threatening arrhythmias.\" \n\n\n  The therapy was also well-tolerated at both dose levels in the study, the company said \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2026 07:14 ET (11:14 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635862200","isCrawlerRequest":true}